Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carol Nieroda

Emergency Medical Services Laurel, MD Medical Doctor

NPI 1649322785 CMS profile 29521

7300 Van Dusen Rd, Emergency Room, Laurel, MD 20707

Open in the dashboard

General payments

$1,315

52 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carol Nieroda of Laurel, MD is reported in the CMS Open Payments database as having received $1,315 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Emergency Medical Services profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59 2
2023 General $58 2
2022 General $345 14
2020 General $187 10
2019 General $665 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Nieroda
  • Emergency Medical Services median
  • Middle half of Emergency Medical Services
  • National median

In program year 2025, general payments to Carol Nieroda were reported at $59. Among 443 Emergency Medical Services profiles paid that year, the median was $72 and the middle half received between $25 and $169.

Show as a table
Year Carol Nieroda Emergency Medical Services median Middle half National median
2019 $665 $62 $20–$162 $163
2020 $187 $37 $17–$119 $114
2021 $0 $58 $20–$133 $132
2022 $345 $61 $21–$156 $149
2023 $58 $58 $21–$173 $160
2024 $0 $62 $24–$161 $164
2025 $59 $72 $25–$169 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $299 14 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $212 4 payments
  3. Novo Nordisk Inc $156 9 payments
  4. AstraZeneca Pharmaceuticals LP $149 8 payments
  5. Amgen Inc. $110 2 payments
  6. Biotronik Inc. $109 1 payment
  7. Amarin Pharma Inc. $52 3 payments
  8. Dexcom, Inc. $40 1 payment
  9. Arbor Pharmaceuticals, Inc. $35 2 payments
  10. Novartis Pharmaceuticals Corporation $27 2 payments
  11. Other $124 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,315 52 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $194 3 payments
  2. Ozempic $156 9 payments
  3. JARDIANCE Diabetes $151 7 payments
  4. AIMOVIG $110 2 payments
  5. BioMonitor $109 1 payment
  6. TRULICITY $108 7 payments
  7. AMYVID $98 4 payments
  8. BEVESPI AEROSPHERE $95 5 payments
  9. RYBELSUS $70 4 payments
  10. FARXIGA $54 3 payments
  11. Other $357 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

880

Median for Emergency Medicine: 88

Drug cost

$22,834

Median for Emergency Medicine: $590

Branded share of claims

7.5%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Potassium Chloride Generic 15 $5,483
Levetiracetam Generic 28 $1,893
Levothyroxine Sodium Generic 82 $1,712
Clonidine Generic 13 $1,367
Albuterol Sulfate Generic 18 $1,203
Metoclopramide Hcl Generic 12 $886
Zolpidem Tartrate Generic 30 $777
Fenofibrate Fenofibrate Nanocrystallized Brand 17 $760
Rosuvastatin Calcium Generic 29 $738
Atorvastatin Calcium Generic 69 $660

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$53,858

Medicare's payments for the services billed

Medicare patients

110

Average age 74

Services billed

700

84 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 35%
Ischemic heart disease 27%
Chronic kidney disease 22%
Atrial fibrillation 19%
Heart failure 14%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medical Services in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record